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representative drug dispensing data from ambulatory care). The statistical analy-
sis was performed using SAS Enterprise Guide 4.1. Results: The average price of 
medicines in the NHS market reduced significantly. Until March 2013, the average 
price of generics reduced 59.0% and brands 12.9%. The margins of pharmacies and 
wholesalers decreased in 2012. As a consequence, the outpatient pharmaceutical 
market decreased € 752 million and the NHS expenditure € 468.1 million, between 
2010 and 2012. However, hospital market in 2012 remains at the same level observed 
in 2010. In the first quarter of 2013, outpatient market reduced another 90.3 million 
€ and NHS expenditure € 49.7 M, of which 21% is due to the reduction of distribution 
margins. ConClusions: Even before the MoU, several changes led to a great reduc-
tion of the public expenditure in 2011. This impact worsened after the MoU, with 
direct effects on the reduction of the remuneration of pharmacies and wholesalers. 
Urgent strategies that ensure the access of patients to medicines while preserving 
the sustainability of both the NHS and the network of pharmacies are required, as 
well as policies to monitor the prescribing, dispensing and utilization of medicines 
and concrete changes in the inpatient NHS expenditure.
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objeCtives: Antimicrobial resistance is still a growing health problem which 
increases morbidity, mortality, and health costs and has been associated with inap-
propriate antibiotic use. In Iran antibiotic prescription rates are high in children and 
antibiotics are the most common medication prescribed. Teaching children about 
the different types of microbes and the increasing problems of antibiotic resistance 
with unnecessary and inappropriate use of antibiotics should not only raise aware-
ness in our future generation of antibiotic users but also in the family environment. 
This study aimed to evaluate the effectiveness of the story telling in improving 
children’s knowledge about rational antibiotic use. Methods: Junior (9–11 years) 
school classes were divided into either control or intervention groups for evaluation 
of the story telling. Students were required to complete identical knowledge ques-
tionnaires at three time points (before, immediately after and 4 weeks after teach-
ing), to assess knowledge change and retention. Teaching, using story books which 
provided by National Committee on Rational Drug Use (NCRUD), was given by junior 
school teachers. Results: A total of 164 junior students, 95 were intervention and 
69 control groups, were studied. The junior story telling demonstrated a significant 
improvement in student’s knowledge (34.5% of change) and there was no significant 
decrease in student knowledge observed after a 4 week period. ConClusions: 
Availability of information on the effectiveness of intervention for improving and 
promoting appropriate antibiotics use can facilitate implementation of strategies in 
this field. Regarding the effectiveness of storytelling, it is therefore recommended 
that decison-maker place greater emphasis on the use of such interventions.
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objeCtives: Hospital formularies are usually the gatekeepers for pharmaceutical 
drugs. Typical majority members of hospital formularies are physicians, although 
most of the time the formulary is chaired by a pharmacist. As German hospitals 
are struggling with a difficult economic environment the question arises: what 
kind of decision-making criteria are applied when pharmaceutical drugs should 
be added to the formulary list? Information regarding this topic is scarce due to 
the sensitive topic of decision-making. Only one study (Thürmann et al., 1997) is 
looking into this for Germany. Methods: a total of 588 public, private and ecclesi-
astic hospitals in Germany have been contacted to participate in an online-survey 
regarding the structure of their hospital formulary, roles of members and applied 
decision-making criteria. Results: Thirty-five of 588 hospitals (6%) have finally 
participated and filled out the complete questionnaire. Out of the 35 participants, 
29 were pharmacists (82.9%) and 6 were physicians (17.1%). 34.3% of the hospitals 
have no guidelines for their decision-making and 65.7% of the hospitals with guide-
lines have written (48.6%) or verbal (17.1%) guidelines. Out of these, 78.3% discuss 
decision-making criteria, but only 47.8% talk about the relative importance of the 
discussed decision-making criteria. Budget impact (82.6%), clinical studies (69.6%) 
and price (65.2%) are the most often mentioned decision-making criteria in the 
guidelines. ConClusions: A third of the participating hospitals do not have guide-
lines for their decision-making process and only half of the guidelines discussing 
decision-making criteria also talk about the relative importance. Hospital formular-
ies in Germany do not seem to be transparent in their decision-making process. In 
addition the top 3 decision criteria in the existing guidelines include 2 economical 
criteria which lead to the question of dominance of economical versus medical or 
other criteria. Further research needs to look at the real applied decision-making 
criteria and how much impact economical criteria have on decision-making in 
German hospital formularies.
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objeCtives: In 2011, the AMNOG law changed the price-setting procedure for drugs 
in Germany. Manufacturers are now required to submit a dossier to the Federal 
Joint Committee (GBA) for newly launched or, upon specific request, already market 
products. The GBA decides on the level of additional benefit which impacts the reim-
bursement price negotiations with German sick funds. The objectives of this study 
were thus to: 1) identify ways in which manufacturers can optimize the benefit 
developing the candidates, with investigational oncology drugs representing the 
largest proportion (53%). Orphan diseases make up the second largest group with 
over a third of publicly disclosed BT therapies. In therapeutic areas with already 
available treatment options, such as Hepatitis C Virus infections and advanced mela-
noma, there is still potential for drug candidates to gain BT designation if they can 
be shown to provide an alternative to effectively treat patients that fail to respond 
to the current standard of care. ConClusions: Our investigation has highlighted 
the FDA’s focus on finding breakthrough candidates within oncology as well as 
rare genetic or orphan diseases that do not currently have adequate treatment 
options. Additionally, candidates offering alternative options to non-responders 
have also secured a place on the list, which is likely to grow as increased interest 
and awareness is generated.
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objeCtives: From October 2013, some pharmaceutical products will be required 
to undergo a medico-economic evaluation in France. The aim of this study was to 
interview key stakeholders involved in this conceptual change in order to under-
stand how this reform will be implemented and how it will affect market access 
in France. Methods: Primary research was conducted between April and June 
2013 with stakeholders from the French National Authority for Health (HAS), the 
Economic and Public Health Evaluation Commission (CEESP), the Transparency 
Commission (TC) and relevant French ministries. Interviews lasted between 45 
and 75 minutes and focused on the methodology for medico-economic assess-
ment and its implications on the French pharmaceutical pricing and reimbursement 
(P&R) process. Results: Medico-economic evaluation in France will be based on 
cost-utility or cost-effectiveness analyses, depending on whether or not quality 
of life is an important outcome. Cost-utility analyses will rely on QALYs (quality-
adjusted life years), whereas cost-effectiveness analyses will rely on survival. The 
medico-economic assessments will inform pricing negotiations, on the one hand, 
and potentially the development of prescribing guidelines, on the other. Medicines 
will be subjected to a medico-economic assessment based on their level of innova-
tion and/or on their financial impact on the health care budget. ConClusions: 
France is formally introducing the QALY into its P&R system; however, this reform 
will come with a twist on the Anglo-Saxon approach, as there will be no associated 
ICER (incremental cost-effectiveness ratio) above which the medicine will not be 
reimbursed. While there is still some level of uncertainty with regards to the medi-
cines that will be subjected to this assessment (as stakeholders have yet to put a 
quantitative value on a “significant impact” on the health care budget), the direction 
of travel is toward greater pressure on pharmaceutical prices.
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objeCtives: In 2011, we saw the introduction of an evidence-based pricing 
approach to new branded pharmaceuticals in Germany. The process arose from the 
Act of the Reform of the Market for Medicinal Products (AMNOG) and all new drugs 
must undergo clinical benefit assessment by the Federal Joint Committee (GBA) fol-
lowed by price negotiation with the German sick fund (GKV-SV) heads depending on 
whether additional benefit has been demonstrated. A review of the final GBA assess-
ments published to date was undertaken and the aim was to evaluate the implica-
tions for manufacturers considering Germany as a launch country. Methods: The 
GBA and IQWIG websites were searched for AMNOG evaluations performed between 
January 2011 to May 2013. Where appropriate the approach taken in the GBA assess-
ment was compared with that of other HTA groups in Europe. Results: The most 
important consideration for a manufacturer is choosing the right comparator in 
their submission, the core evidence document in this process. A number of drugs 
have been compared to the wrong treatment and subsequently were found to have 
no additional benefit. Some submissions chose the appropriate comparator but 
only for certain subgroups, leading to a reduced overall benefit for the new drug. 
Like most HTA groups, the preference is for mortality, morbidity and side effects 
evidence from head-to-head trials, however GBA appear to give little considera-
tion to quality of life evidence. The review also revealed that GBA make decisions 
that are independent of other HTA bodies and sometimes reject recommendations 
of its own evidence review group, IQWIG. ConClusions: Early engagement with 
GBA to agree an appropriate comparator, patient population and clinical outcome 
measures is very important to improve chances of a positive assessment. However, 
the requirements of the GBA process should be balanced with those of other key 
markets as part of the drug’s global PRA strategy.
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objeCtives: The Memorandum of Understanding signed in May 2011, between the 
Portuguese Government and the International Authorities, increased requirements 
to reduce the public expenditure with medicines. These measures included the 
major change in margins distribution system. This study aims to: 1) describe the 
MoU measures related to medicines; 2) analyze public expenditure and impact of 
distribution margins reductions on medicines public expenditure, due to MoU and 
legislative changes in Portugal. Methods: Descriptive study with updates to the 
MoU and published legislation. Market analysis and simulations were computed 
based on the Pharmacy Sales Information System (a nationwide database with 
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and European countries. Methods: Comparison of miligram based prices analy-
sis between European countries done by Intelligent Health System(IHS) was used. 
The analysis of IHS included Germany, France, United Kingdom(UK), Spain and 
Italy(EU5). Comparison was done with taken row data of analysis EU5 and Turkey 
average milligram retail prices of Ceftriaxone, Clopidogrel, Esomeprazole, Fentanyl, 
Lamotrigine, Levofloxacin, Metformin, Venlafaxine, Letrozole and Olanzapine 
molecules. Results: It has been reported that compared 10 molecules highest 
average miligram based prices of Esomeprazole(0,043 € ), Levofloxacin(0,058 € ) and 
Clopidogrel(0,0083 € ) molecules belong to Turkey, Lamotrigine(0,01 € ) belongs to 
Germany. The highest average miligram based prices of other 6 molecules belong 
to UK with following; Ceftriaxone(0,0196 € ), Fentanyl(0,186 € ), Letrozole(1,24 € ), 
Metformine(0,00013 € ), Venlafaxine(0,0074 € ), Olanzapine(0,261 € ). ConClusions: 
It has known that because of UK used free pricing mechanism on drugs, prices of 
drugs are higher than other compared countries. This sitiuation established on the 
anaylsis. But despite of Turkish Government policy decisions; it is important indicia-
tion that 3 drugs represents highest prices out 10 drugs. Reference pricing system 
applied based on box price. Better control mechanism may achievable if miligram 
based pricing apply in Turkey. On the other hand because of the study only consist 
retail sales prices the evaluation should be done from point of reimbursement 
prices on future studies.
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objeCtives: The expiration of biotech drugs patent has led to the creation of drugs 
copies of originator products, defined ‘biosimilars’. No European country allows 
automatic substitution between the originator and the biosimilar. In Italy, due to 
the lack of a national legislation, some Regions have issued directives to encour-
age the use of biosimilars, recognizing a potential saving of resources. Campania 
Region was the first region to legislate on the matter, (decree no. 15 of 11.30.2009) 
supporting the prescription of biosimilars to the naive patient. The aim of our 
study is to describe trends in biosimilars consumption in Campania region and 
evaluate how biosimilar products are replacing the originators in the respective 
markets. Methods: IMS Health regional database was used to analyze biosimi-
lar drugs consumption patterns (erythropoietins, G-CSF, somatropin) in the years 
2009- 2012. Information was retrieved about different distribution channels (retail, 
direct distribution, hospital). Consumptions are expressed in Counting Units (CU) 
and trends have been calculated using Compound Average Grow Rate (CAGR). The 
study especially focused on consumption trends of erythropoietin (ATC B03XA) in 
the years 2009-2012. Results: In 2012 the penetration rate of biosimilars was 40.1% 
(evaluated as the biosimilars share of the total erythropoietins, G-CSF, somatropin 
market). These values are double than those at national level, that are estimated to 
be 19.7% of consumption. Focus on erythropoietin trends showed a strong increase 
in biosimilars consumption (451 CU in 2009 vs 140,327 CU in 2012) after the introduc-
tion of regional measures to promote the prescription of biosimilars to the naive 
patient. In 2012, biosimilar erythropoietins and reference drugs show similar market 
shares (37.0% and 33.7% of the total erythropietins market respectively) showing 
a high substitution effect. ConClusions: Our analysis outlines the significant 
effects of regional measures on market penetration rates of biosimilars.
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objeCtives: Estimation of the direct and indirect savings generated by parallel 
importing (PI) of pharmaceutical products in public pharmacies in Poland, and esti-
mation of the savings for the payer in the case of reimbursed drugs. Methods: IMS 
Health Poland National Sales Data (2005-2012) and data from respective reimburse-
ment lists were used for all calculations. Direct savings were estimated considering 
all PI products sold in public pharmacies(433 products, 1550 SKUs). To avoid overes-
timation, only 18 products that passed restrictive criteria were used for calculations 
of indirect savings. Twenty-seven reimbursed products were used for the payer 
savings calculations. Direct savings were calculated as a difference between PI and 
reference product prices multiplied by the number of packs of PI product. Indirect 
savings were calculated as a difference between the reference product price and 
the theoretical reference product price (i.e. prices in a hypothetical situation where 
there is no price pressure caused by PI – calculated using linear regression). Indirect 
savings considered only those products which met the criteria of the reference 
product’s price decrease of at least 5% within 3 months prior to, or after, the appear-
ance of the PI product. Results: Study revealed that the savings generated by the 
PI of pharmaceuticals in Poland between 2005-2012 may be estimated at the level 
of EUR 146m (direct savings EUR 46m and indirect savings EUR 100m). Savings for 
the payer calculated for reimbursed products between 2008-2012 reached the level 
of EUR 0.06m. ConClusions: This is the first study estimating direct and indirect 
savings coming from PI phenomena covering all years since PI was reinforced by 
Poland’s accession to the EU. It has been found very interesting that indirect sav-
ings tend to be substantially higher that direct ones. This indicates that high price 
pressure is created by PI, and affects the prices of reference products.
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assessment outcomes, 2) analyze correlations between additional benefit, budget 
impact and negotiated rebate. Methods: To achieve objective 1, assessments by 
the GBA and the IQWiG (Institute for Quality and Efficiency in Healthcare) (source: 
GBA website) were scanned for key trends. To achieve objective 2, list and post-
negotiation prices were extracted from the Lauer-Taxe (German price database). 
For the 10 agents that had so far completed price negotiations, these were mapped 
against additional benefit and the budget impact (annual therapy costs as stated 
in GBA assessment). Results: The results linked to objective 1, which were more 
qualitative in nature, allowed for the extraction of 5 key learnings for manufacturers 
to keep in mind. The results associated with objective 2 showed no link between 
additional benefits granted and negotiated rebate but did reveal price impacting 
parameters apart from budget impact. ConClusions: Concerning objective 1, the 
ways in which manufacturers can attempt to optimize benefit outcomes include: 1. 
Focus on comparator choice, 2. Focus on hard endpoints, 3. Make patient segmenta-
tion more solid, 4. Expect independent action of GBA and IQWiG and 5. Accept that 
there is no methodological standard for the definition of an additional benefit. 
Regarding objective 2, we concluded that budget impact, influenced primarily by 
target population size, annual therapy costs and drug price, is an – if not the most 
important driver in the negotiation.
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objeCtives: To assess how drug innovation is rewarded and how it is impacted 
by cost-containment policies. Methods: Manufacturer prices per unit of pack-
age and strengths were compared and assessed in a basket of 97 innovative drugs 
approved by the European Medicines Agency (EMA) since 2000. The products were 
still patent protected, and available in each of the top 5 European pharmaceutical 
markets. Results: Prices of innovative drugs in Germany were still the highest and 
had a benchmark price index of 100. In France, when drugs were deemed innova-
tive, premium prices were granted – resulting in a price index of 94 – but signifi-
cantly decreased over time. While prices at launch in Italy, Spain and the UK were 
commonly lower – with price indexes of 89, 88 and 86 respectively - they tended 
to remain constant over time. ConClusions: Despite the fact that governments 
in developed markets are attempting to lower prices, differences still exist across 
the largest markets, enabling pharmaceutical companies to implement differential 
and protective pricing strategies. In Germany, time to market is comparatively fast 
and premium prices at launch have been granted. In future, the AMNOG reform 
will complicate this picture, although pricing premiums have still been achieved 
for drugs deemed innovative that have gone through the full AMNOG process. In 
France, although prices are relatively high at launch, they drop at time of renewal 
and innovation is granted to a limited number of drugs. Prices have been compara-
tively low at launch but remain constant in Italy and Spain, reflecting the fact that 
price cuts in those countries have often been directed towards generics, although 
these are still considered high-risk markets. In the UK, it remains to be seen how 
the value-based pricing reform will impact prices.
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objeCtives: To describe availability of orphan drugs in France, UK and Germany and 
to compare agencies’ assessments and prices. Methods: All the products designated 
as orphan drugs by the European Commission and commercialized at least in one of 
the three countries were included in the study. Comparison of prices is made per dos-
age and is based on prices per standard unit, using IMS MIDAS database. Comparison 
of assessments is based on Transparency Committee opinions, NICE guidances and 
IQWIG benefit assessments. Results: Sixty-two products (103 dosages/forms) were 
included in this study; 47 (76%; 84 dosages/forms) are commercialized in the 3 coun-
tries, 8 (13%) products in only 2 countries (6 both in Germany and UK and 2 both in 
Germany and France) and 7 (11%) only in 1 country (6 in Germany only and 1 in France 
only). Among the 84 products/dosage/forms available in the three countries, most of 
them are available at hospital (respectively 68, 70 and 77 in Germany, France and UK) 
but those available through retail pharmacists are much numerous in Germany (72 of 
them) than in France (29) or UK (30). German and UK manufacturer March 2013 retail 
prices more often higher than French one, despite the fact that among the 49 orphan 
drugs commercialized in France, 31 are innovative products (ASMR rate I to III). For 
instance, French assessment of pirfenidone was less favorable than the Germans’one, 
and German price is thus +65.2% higher than French price. French and UK HTA assess-
ments for azacitidine were both positive and led to similar prices. ConClusions: 
Most orphan drugs are available in the three studied countries but accessibility to 
them seems to be different and depends on HTA results.
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objeCtives: The reference pricing system is used for setting drug prices in Turkey 
since 2006. There are 5 reference countries following; Spain, Italy, Germany, France 
and Greece. Except those countries, manufactured or imported countries may be 
used as reference countries. Reference prices are reviewed time by time and may 
be subject to certain alterations, but evaluation of box prices may be different if 
evaluation made based on milligram. The aim of this study is to evaluate differ-
ences of average milligram sales prices of some generic medicines between Turkey 
